| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| Other Sizes |
| Targets |
As a phase-transfer catalyst, N-Benzylcinchoninium chloride does not target a specific protein or enzyme in biological systems. Its utility is based on its chemical properties as a chiral quaternary ammonium salt rather than as a drug targeting specific molecular targets. The compound facilitates the transfer of reactants between immiscible phases (e.g., aqueous and organic) in organic synthesis, enabling reactions to proceed under mild conditions. The chiral nature of the cinchona alkaloid scaffold allows for asymmetric induction in reactions, but this is a chemical catalysis mechanism rather than a biological target engagement.
|
|---|---|
| ln Vitro |
The in vitro activity of N-Benzylcinchoninium chloride is its function as a chiral phase-transfer catalyst in organic synthesis. The compound is involved in a variety of asymmetric transformations including: enantioselective alkylation of malonic diester with alkyl halides, hydrolysis of enol esters, asymmetric 6π electrocyclization for synthesis of functionalized indolines, asymmetric Michael addition, alkylation of monosubstituted indolinones with alkyl halides, and asymmetric destruction and kinetic resolution of 1-benzylated Reissert compounds. The compound's chirality enables the formation of enantiomerically enriched products in these reactions, making it a valuable tool for asymmetric synthesis.
|
| ln Vivo |
No significant in vivo activity has been reported for N-Benzylcinchoninium chloride as a therapeutic agent. The compound is primarily utilized as a chemical catalyst for organic synthesis rather than a pharmacologically active compound. It is not intended for therapeutic use in living organisms.
|
| Enzyme Assay |
In vitro assays for N-Benzylcinchoninium chloride are not typically performed in the context of enzyme or receptor binding, as the compound is a chemical catalyst rather than a drug targeting specific biological targets. The compound is used in chemical reactions where it acts as a phase-transfer catalyst to facilitate transformations between immiscible phases. Reaction monitoring is typically performed by analytical techniques such as TLC, HPLC, or GC to assess conversion and enantiomeric excess.
|
| Cell Assay |
For in vitro cellular experiments, N-Benzylcinchoninium chloride is not typically used in cell-based assays. The compound is primarily used as a chemical reagent in organic synthesis rather than in biological studies.
|
| Animal Protocol |
In vivo animal experiments with N-Benzylcinchoninium chloride are not commonly performed, as the compound is primarily used as a chemical catalyst rather than a therapeutic candidate.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of N-Benzylcinchoninium chloride have not been characterized, as the compound is a research-use chemical reagent rather than a drug candidate. The compound has a molecular weight of 420.97 g/mol and is a solid at room temperature with a melting point of 256°C (dec.). It should be stored in an inert atmosphere at room temperature in a cool and dark place below 15°C.
|
| Toxicity/Toxicokinetics |
The compound is classified as a combustible solid (Storage Class 11) with a WGK rating of 3. It is intended for research use only and not for human therapeutic or diagnostic applications. Standard laboratory safety precautions should be observed when handling this chemical reagent, including the use of dust mask type N95, eyeshields, and gloves.
|
| Additional Infomation |
N-Benzylcinchoninium chloride (CAS#: 69221-14-3) is a chiral phase-transfer catalyst widely used in organic synthesis, particularly in asymmetric reactions such as enantioselective alkylation, Michael addition, and asymmetric electrocyclization. It is derived from cinchona alkaloids and is valuable for preparing enantiomerically enriched compounds. The compound has no clinical or therapeutic applications.
|
| Molecular Formula |
C26H29CLN2O
|
|---|---|
| Molecular Weight |
420.98
|
| Exact Mass |
420.196
|
| CAS # |
69221-14-3
|
| PubChem CID |
11384639
|
| Appearance |
Typically exists as solid at room temperature
|
| Melting Point |
256ºC (dec.)(lit.)
|
| Index of Refraction |
168.5 ° (C=0.4, MeOH:H2O=1:5)
|
| LogP |
1.842
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
30
|
| Complexity |
573
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
[Cl-].O([H])[C@@]([H])(C1=C([H])C([H])=NC2=C([H])C([H])=C([H])C([H])=C12)[C@@]1([H])C([H])([H])C2([H])C([H])([H])C([H])([H])[N+]1(C([H])([H])C1C([H])=C([H])C([H])=C([H])C=1[H])C([H])([H])C2([H])C([H])=C([H])[H]
|
| InChi Key |
FCHYSBWCOKEPNQ-YGNISETGSA-M
|
| InChi Code |
InChI=1S/C26H29N2O.ClH/c1-2-20-18-28(17-19-8-4-3-5-9-19)15-13-21(20)16-25(28)26(29)23-12-14-27-24-11-7-6-10-22(23)24;/h2-12,14,20-21,25-26,29H,1,13,15-18H2;1H/q+1;/p-1/t20-,21-,25+,26-,28?;/m0./s1
|
| Chemical Name |
(S)-[(2R,4S,5R)-1-benzyl-5-ethenyl-1-azoniabicyclo[2.2.2]octan-2-yl]-quinolin-4-ylmethanol;chloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3754 mL | 11.8770 mL | 23.7541 mL | |
| 5 mM | 0.4751 mL | 2.3754 mL | 4.7508 mL | |
| 10 mM | 0.2375 mL | 1.1877 mL | 2.3754 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
